UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis

Nature communications, 2020-09, Vol.11 (1), p.4767-4767, Article 4767

2020

Volltextzugriff (PDF)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2023-02, Vol.75 (2), p.253-265

2023

Volltextzugriff (PDF)

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

Proceedings of the National Academy of Sciences - PNAS, 2015-08, Vol.112 (34), p.10768-10773

2015

Volltextzugriff (PDF)

Activation‐Induced Killer Cell Immunoglobulin‐like Receptor 3DL2 Binding to HLA–B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis

Arthritis & rheumatology (Hoboken, N.J.), 2016-04, Vol.68 (4), p.901-914

2016

Volltextzugriff (PDF)

Context-specific regulation of surface and soluble IL7R expression by an autoimmune risk allele

Nature communications, 2019-10, Vol.10 (1), p.4575-11, Article 4575

2019

Volltextzugriff (PDF)

Persistent stromal fibroblast activation is present in chronic tendinopathy

Arthritis research & therapy, 2017-01, Vol.19 (1), p.16-16, Article 16

2017

Volltextzugriff (PDF)

LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis

Lupus science & medicine, 2024-03, Vol.11 (Suppl 1), p.A169-A170

2024

Volltextzugriff (PDF)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design

Trials, 2021-03, Vol.22 (1), p.185-185, Article 185

2021

Volltextzugriff (PDF)

Correction: Targeting DORIS Remission and LLDAS in SLE: A Review

Rheumatology and therapy., 2024-08, Vol.11 (4), p.1059-1061

2024

Volltextzugriff (PDF)

1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab

Lupus science & medicine, 2024-05, Vol.11 (Suppl 2), p.A114-A115

2024

Volltextzugriff (PDF)

Targeting DORIS Remission and LLDAS in SLE: A Review

Rheumatology and therapy., 2023-12, Vol.10 (6), p.1459-1477

2023

Volltextzugriff (PDF)

Novel Therapeutic Targets in Axial Spondyloarthritis

Current treatment options in rheumatology, 2018, Vol.4 (2), p.174-182

2018

Volltextzugriff (PDF)

Expression of aberrant HLA-B27 molecules is dependent on B27 dosage and peptide supply

Annals of the rheumatic diseases, 2014-04, Vol.73 (4), p.763-770

2014

Volltextzugriff (PDF)

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

Clinical and experimental rheumatology, 2024-08, Vol.42 (8), p.1635

2024

Volltextzugriff (PDF)

Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology

Annals of the rheumatic diseases, 2021-12, Vol.80 (12), p.1505-1510

2021

Volltextzugriff (PDF)

Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce

Nature reviews. Rheumatology, 2023-09, Vol.19 (9), p.592-602

2023

Volltextzugriff (PDF)

Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid

Annals of the rheumatic diseases, 2021-12, Vol.80 (12), p.1559-1567

2021

Volltextzugriff (PDF)

Personalized medicine — a new reality in psoriatic arthritis?

Nature reviews. Rheumatology, 2018-08, Vol.14 (8), p.449-451

2018

Volltextzugriff (PDF)

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Annals of the rheumatic diseases, 2024-08, Vol.83 (8), p.1018-1027

2024

Volltextzugriff (PDF)

The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis

Modern rheumatology, 2024-07, Vol.34 (4), p.720-731

2024

Volltextzugriff (PDF)

02.35Time of flight mass cytometry (cytof) and rna sequencing interrogation of 'pathogenic' gm-csf lymphocytes in human spondyloarthritis

Annals of the rheumatic diseases, 2017-03, Vol.76 (Suppl 1), p.A22-A23

2017

Volltextzugriff (PDF)

02.35 Time of flight mass cytometry (cytof) and rna sequencing interrogation of ‘pathogenic’ gm-csf lymphocytes in human spondyloarthritis

Annals of the rheumatic diseases, 2017-03, Vol.76 (Suppl 1), p.A22

2017

Volltextzugriff (PDF)

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis

Annals of the rheumatic diseases, 2016-05, Vol.75 (5), p.916-923

2016

Volltextzugriff (PDF)

03.20Identification of chromatin modifying mechanisms in inflammatory macrophages in rheumatoid arthritis

Annals of the rheumatic diseases, 2017-03, Vol.76 (Suppl 1), p.A38-A38

2017

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

Zeitschrift / SerieCommunications Biology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(21)

Publikationsform

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Rheumatology
(18)
Life Sciences & Biomedicine
(17)
Humans
(15)
Adult
(10)
Male
(9)
Female
(8)
Middle Aged
(8)
Patients
(7)
Clinical Trials
(6)
Disease
(6)
Treatment Outcome
(6)
Aged
(5)
Arthritis
(5)
Lupus
(5)
Lymphocytes
(5)
Medicine
(5)
Medicine & Public Health
(5)
Antibodies, Monoclonal, Humanized - Adverse Effects
(4)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

Activation‐Induced Killer Cell Immunoglobulin‐like Receptor 3DL2 Binding to HLA–B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis

Context-specific regulation of surface and soluble IL7R expression by an autoimmune risk allele

Persistent stromal fibroblast activation is present in chronic tendinopathy

LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design

Correction: Targeting DORIS Remission and LLDAS in SLE: A Review

1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab

Targeting DORIS Remission and LLDAS in SLE: A Review

Novel Therapeutic Targets in Axial Spondyloarthritis

Expression of aberrant HLA-B27 molecules is dependent on B27 dosage and peptide supply

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology

Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce

Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid

Personalized medicine — a new reality in psoriatic arthritis?

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis

02.35Time of flight mass cytometry (cytof) and rna sequencing interrogation of 'pathogenic' gm-csf lymphocytes in human spondyloarthritis

02.35 Time of flight mass cytometry (cytof) and rna sequencing interrogation of ‘pathogenic’ gm-csf lymphocytes in human spondyloarthritis

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis

03.20Identification of chromatin modifying mechanisms in inflammatory macrophages in rheumatoid arthritis

Aktive Filter

Suchergebnisse filtern